Related Experiment Video
Updated: Feb 4, 2026

Studying Wnt Signaling During Patterning of Conducting Airways
Published on: October 16, 2016
Potent in vivo lung cancer Wnt signaling inhibition via cyclodextrin-LGK974 inclusion complexes
Pedro P G Guimaraes1, Mingchee Tan2, Tuomas Tammela3
1Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, United States; Department of Chemical Engineering, MIT, Cambridge, MA, United States; Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil; Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, United States.
Abstract:
Activation of the Wnt signaling pathway promotes lung cancer progression and contributes to poor patient prognosis. The porcupine inhibitor LGK974, a novel orally bioavailable cancer therapeutic in Phase I clinical trials, induces potent Wnt signaling inhibition and leads to suppressed growth and progression of multiple types of cancers. The clinical use of LGK974, however, is limited in part due to its low solubility and high toxicity in tissues that rely on Wnt signaling for normal homeostasis. Here, we report the use of host-guest chemistry to enhance the solubility and bioavailability of LGK974 in mice through complexation with cyclodextrins (CD). We assessed the effects of these complexes to inhibit Wnt signaling in lung adenocarcinomas that are typically driven by overactive Wnt signaling. 2D 1H NMR confirmed host-guest complexation of CDs with LGK974. CD:LGK974 complexes significantly decreased the expression of Wnt target genes in lung cancer organoids and in lung cancer allografts in mice. Further, CD:LGK974 complexes increased the bioavailability upon oral administration in mice compared to free LGK974. In a mouse lung cancer allograft model, CD:LGK974 complexes induced potent Wnt signaling inhibition with reduced intestinal toxicity compared to treatment with free drug. Collectively, the development of these complexes enables safer and repeated oral or parenteral administration of Wnt signaling inhibitors, which hold promise for the treatment of multiple types of malignancies.
Insights
Host-guest chemistry enhances LGK974 solubility and bioavailability. This Wnt signaling inhibitor shows promise for safer lung cancer treatment with reduced toxicity.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Wnt signaling pathway activation drives lung cancer progression and poor prognosis.
- LGK974, an orally bioavailable porcupine inhibitor, effectively suppresses Wnt signaling but faces limitations due to low solubility and high toxicity.
- Targeting Wnt signaling is crucial for effective cancer therapeutics.
Purpose of the Study:
- To enhance the solubility and bioavailability of LGK974 using host-guest chemistry with cyclodextrins (CD).
- To evaluate the efficacy of CD:LGK974 complexes in inhibiting Wnt signaling in lung adenocarcinoma models.
- To assess the safety profile and therapeutic potential of these complexes for cancer treatment.
Main Methods:
- Host-guest complexation of LGK974 with cyclodextrins (CD) confirmed by 2D 1H NMR.
- In vitro assessment of Wnt target gene expression in lung cancer organoids.
- In vivo evaluation in mouse lung cancer allograft models, including bioavailability and toxicity studies.
Main Results:
- CD:LGK974 complexes significantly reduced Wnt target gene expression in lung cancer organoids and allografts.
- Complexation with CDs enhanced LGK974 oral bioavailability in mice.
- CD:LGK974 complexes demonstrated potent Wnt signaling inhibition with reduced intestinal toxicity compared to free LGK974.
Conclusions:
- Host-guest chemistry effectively improves LGK974 solubility and bioavailability.
- CD:LGK974 complexes offer a promising strategy for safer and repeated administration of Wnt signaling inhibitors.
- These complexes hold significant potential for the treatment of various malignancies, including lung cancer.
Related Concept Videos
Canonical Wnt Signaling Pathway
Non-Canonical Wnt Signaling Pathways
Assembly of Signaling Complexes
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Inclusive Fitness
Cell Inclusions
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

